Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment

Clin Chest Med. 2013 Jun;34(2):217-28. doi: 10.1016/j.ccm.2013.02.003. Epub 2013 Apr 8.

Abstract

Tuberculosis (TB) is the leading cause of opportunistic infection and mortality among HIV-infected persons. Screening for symptoms of TB in people with HIV infection, use of isoniazid preventive therapy for those with latent TB infection, earlier diagnosis and treatment of active TB disease, and early initiation of antiretroviral therapy are essential for controlling the spread of TB. Treatment of HIV-related TB is complicated by overlapping drug toxicities and drug-drug interactions between antiretroviral therapy and anti-TB therapy and risk for development of immune reconstitution inflammatory disease. This review provides an overview of the prevention and treatment of TB in HIV-infected persons.

Publication types

  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / diagnosis
  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / prevention & control
  • Anti-Retroviral Agents / therapeutic use*
  • Antitubercular Agents / therapeutic use*
  • Drug Interactions
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / etiology
  • Isoniazid / therapeutic use
  • Latent Tuberculosis
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / prevention & control
  • Virus Activation

Substances

  • Anti-Retroviral Agents
  • Antitubercular Agents
  • Isoniazid